Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$545.96 USD

545.96
428,791

+2.64 (0.49%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Icon PLC (ICLR) Up 2.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Elevance Health (ELV) Up 7.3% Since Last Earnings Report?

by Zacks Equity Research

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%

by Zacks Equity Research

Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

Select Medical's (SEM) Stock Down 16.9% Despite Q2 Earnings Beat

by Zacks Equity Research

Select Medical (SEM) expects its adjusted EBITDA between $845 million and $885 million for 2024, the mid-point of which implies a 7.1% rise from the 2023 reported figure of $807.4 million.

Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat

by Zacks Equity Research

Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.

Cigna (CI) Q2 Earnings Top on Specialty Business Strength

by Zacks Equity Research

Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.

Ensign Group (ENSG) Q2 Earnings Beat on Occupancy, Stock Up 7.2%

by Zacks Equity Research

Ensign Group's (ENSG) second-quarter results benefit from improved occupancy and skilled services revenue. Higher expenses partially offset the results.

Kaibalya Pravo Dey headshot

UnitedHealth (UNH) Q2 Success: A Turnaround Worth Investing in?

by Kaibalya Pravo Dey

UnitedHealth (UNH) is navigating its challenges effectively, maintaining a positive outlook for the future while demonstrating a strong commitment to its clients and shareholders.

Centene (CNC) Q2 Earnings Miss on Declining Medicaid Membership

by Zacks Equity Research

Centene's (CNC) second-quarter earnings suffer from rising operating expenses and a decline in Medicaid membership levels. Improved Marketplace membership growth partially offset the negatives.

Community Health (CYH) Q2 Earnings Miss on Lower Patient Days

by Zacks Equity Research

Community Health's (CYH) second-quarter earnings suffer a setback from lower admissions and patient days. Improved occupancy levels partially offset the negatives.

Universal Health (UHS) Q2 Earnings Beat on Acute Care Strength

by Zacks Equity Research

Universal Health's (UHS) second-quarter results benefit from the rising number of patients in the Acute Care Unit. Declining admissions in the Behavioral Health segment partially offset the positives.

Tenet (THC) Q2 Earnings Beat on Patient Volumes, '24 EPS View Up

by Zacks Equity Research

Tenet Healthcare's (THC) Q2 results reflect net revenue per case growth, higher pricing yield and a decline in overall expenses. It expects 2024 adjusted EPS within $10.41-$11.12, up from the previous guidance of $8.37-$9.41.

The Zacks Analyst Blog Highlights S&P Global, Honeywell International, Elevance Health and Sypris Solutions

by Zacks Equity Research

S&P Global, Honeywell International, Elevance Health and Sypris Solutions are part of the Zacks Top Analyst Blog.

Sheraz Mian headshot

Q2 Earnings Season Scorecard and Today's Analyst Reports for Honeywell, Elevance Health & Others

by Sheraz Mian

Today's Research Daily features a real-time earnings season scorecard and updated research reports S&P Global (SPGI), Honeywell (HON) and Elevance Health(ELV), as well a micro-cap stock Sypris Solutions, Inc. (SYPR).

Boston Scientific (BSX) Banks on Global Expansion, Innovation

by Zacks Equity Research

In EMEA, Boston Scientific (BSX) is successfully expanding its base, banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand.

Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

GE HealthCare (GEHC) New Deal to Aid Its Ultrasound Portfolio

by Zacks Equity Research

GE HealthCare (GEHC) announces that it has entered into an agreement to acquire Intelligent Ultrasound's AI software business to strengthen its ultrasound portfolio.

Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software

by Zacks Equity Research

Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.

Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense

by Zacks Equity Research

Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.

Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance

by Zacks Equity Research

Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Elevance Health (ELV) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 1.30% and 0.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Expands Its Facility Capabilities in Germany

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.